| Literature DB >> 23344196 |
Mohammad Emad Azab1, Mohamed M Youssef, Eman A El-Bordany.
Abstract
Aiming for the synthesis of new heterocyclic compounds containing a sulfonamido moiety suitable for use as antibacterial agents, the precursor ethyl {[4-N-(4,6-dimethylpyrimidin-2-yl)sulfamoyl]phenylazo}cyanoacetate was reacted with a variety of active methylene compounds producing pyran, pyridine and pyridazine derivatives. Also, the reactivity of the precursor hydrazone towards hydrazine derivatives to give pyrazole and oxazole derivatives was studied. On the other hand, treatment of the same precursor with urea, thiourea and/or guanidine hydrochloride furnished pyrimidine and thiazine derivatives, respectively. The newly synthesized compounds were tested for antibacterial activity, whereby eight compounds were found to have high activities.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23344196 PMCID: PMC6270435 DOI: 10.3390/molecules18010832
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Scheme 1Diazotization and coupling of sulfamethazine; formation of 3.
Scheme 2Cyclization of the arylazo cyanoacatate derivative 3 with active methylene compounds and β-dinitriles; formation of substituted pyrans, pyridines and pyridazines.
Scheme 3Cyclization of the arylazo cyanoacatate derivative 3 with amino compounds; formation of substituted pyrazoles, isoxazoles, pyrazolopyrimidines, pyrimidines and 1,3-thiazines.
Antibacterial activity of the synthesized compounds: Agar diffusion method.
| Compound No. | Gram positive | Gram negative | ||
|---|---|---|---|---|
| ++ | ++ | ++ | ++ | |
| - | - | + | + | |
| ++ | ++ | + | + | |
| + | + | + | + | |
| + | - | + | + | |
| + | + | - | - | |
| + | + | + | + | |
| +++ | +++ | +++ | +++ | |
| ++ | +++ | ++ | ++ | |
| ++ | ++ | ++ | ++ | |
| +++ | ++ | + | ++ | |
| + | + | + | + | |
| ++ | ++ | +++ | +++ | |
| ++ | +++ | +++ | ++ | |
| + | + | +++ | + | |
| ++ | ++ | +++ | +++ | |
The width of the zone of inhibition indicates the potency of antibacterial activity; (-) no antibacterial activity; (+) mild activity with the diameter of the zones equal to 0.5–0.8 cm, (++) moderate activity with the diameter of the zones equal to 1.1–1.2 cm; (+++) marked high activity with the diameter of the zones equal to 1.8–2.0 cm.
Antibacterial activity of the synthesized compounds.
| Comp. No. | Inhibition zone (mm) | |||
|---|---|---|---|---|
| Gram-positive | Gram-negative | |||
| 12 | 10 | 11 | 8 | |
| 0 | 0 | 5 | 7 | |
| 13 | 11 | 6 | 6 | |
| 3 | 5 | 3 | 4 | |
| 6 | 7 | 2 | 6 | |
| 6 | 6 | 8 | 5 | |
| 5 | 7 | 7 | 8 | |
| 17 | 16 | 16 | 18 | |
| 15 | 12 | 13 | 11 | |
| 12 | 11 | 10 | 10 | |
| 16 | 12 | 7 | 11 | |
| 7 | 7 | 5 | 8 | |
| 13 | 11 | 16 | 17 | |
| 17 | 12 | 18 | 14 | |
| 9 | 8 | 15 | 7 | |
| 12 | 13 | 17 | 15 | |
| 18 | 19 | 22 | 21 | |
| 19 | 22 | 24 | 20 | |
The sensitivity of microorganisms to the tested compounds is identified in the following manner: Highly sensitive = Inhibition zone 15–20 mm; Moderately sensitive = Inhibition zone: 10–15 mm; Slightly sensitive = Inhibition zone: 5–10 mm; Not sensitive = Inhibition zone: 0–5 mm; Each result represents the average of triplicate readings.